pSivida plunges on FDA knock-back

Stocks in Perth-based biotech pSivida have halved in value after the United States Food and Drug Administration declined to approve its treatment for back-of-the-eye problems associated with diabetes.At close of trade today pSivida’s stock had lost 48.7 per cent, to trade at $2.10.